Precision appoints John Hubbard, PhD, as Board of Directors Chair

Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.

Zydus receives final approval from the USFDA for Olanzapine

Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions

Keytruda + chemotherapy improved overall survival versus chemotherapy alone as for advanced malignant pleural mesothelioma

For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma

IIT Kanpur and Reliance Life Sciences join forces to revolutionize gene therapy for hereditary eye diseases

IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases

Bachem raises $116 million through capital increase

Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies

Marksans Pharma announces USFDA approval for Famotidine Tablets

Marksans' OTC Famotidine Tablets USP are acid reducers

Zydus receives final approval from the USFDA for Erythromycin Tablets

Erythromycin Tablets USP, 250 mg and 500 mg are used to prevent and treat infections in many different parts of the body

Alembic receives USFDA tentative approval for Brexpiprazole Tablets

Alembic receives USFDA final approval for Prazosin Hydrochloride Capsules

Prazosin Hydrochloride Capsule is indicated for the treatment of hypertension, to lower blood pressure

Eugia Pharma receives USFDA approval for Lenalidomide Capsules

The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone